[FG] Niess Jan

Woelfel, S. et al. (2024) ‘STAR LIGHT Study: XBB.1.5 COVID-19 mRNA Vaccines Boost Systemic but Not Mucosal Immunity Against the SARS-CoV-2 JN.1 Variant in Patients with Chronic Liver Disease’, Vaccines, 12(11), p. 1241. Available at: https://doi.org/10.3390/vaccines12111241.

Rubin, D.T. et al. (2024) ‘Deployment of an Artificial Intelligence Histology Tool to Aid Qualitative Assessment of Histopathology Using the Nancy Histopathology Index in Ulcerative Colitis’, Inflammatory Bowel Diseases [Preprint]. Available at: https://doi.org/10.1093/ibd/izae204.

Melhem, H. and Niess, J.H. (2024) ‘Eosinophilic Esophagitis and Inflammatory Bowel Disease: What Are the Differences?’, International Journal of Molecular Sciences, 25(15), p. 8534. Available at: https://doi.org/10.3390/ijms25158534.

Woelfel, S. et al. (2024) ‘Systemic and Mucosal Immunogenicity of Monovalent XBB.1.5-Adapted COVID-19 mRNA Vaccines in Patients with Inflammatory Bowel Disease’, Vaccines, 12(7), p. 774. Available at: https://doi.org/10.3390/vaccines12070774.

Byndloss, Mariana et al. (2024) ‘The gut microbiota and diabetes: research, translation, and clinical applications – 2023 Diabetes, Diabetes Care, and Diabetologia Expert Forum’, Diabetologia [Preprint]. 24.06.2024. Available at: https://doi.org/10.1007/s00125-024-06198-1.

Baldrich, Adrian et al. (2024) ‘Post-transplant Inflammatory Bowel Disease Associated with Donor-Derived TIM-3 Deficiency’, Journal of Clinical Immunology, 44(3). Available at: https://doi.org/10.1007/s10875-024-01667-z.

Baldrich, Adrian et al. (2024) ‘Post-transplant Inflammatory Bowel Disease Associated with Donor-Derived TIM-3 Deficiency’, Journal of Clinical Immunology, 44. Available at: https://doi.org/10.1007/s10875-024-01667-z.

Byndloss, Mariana et al. (2024) ‘The Gut Microbiota and Diabetes: Research, Translation, and Clinical Applications—2023 Diabetes, Diabetes Care, and Diabetologia Expert Forum’, Diabetes, 73, pp. 1391–1410. Available at: https://doi.org/10.2337/dbi24-0028.

Byndloss, Mariana et al. (2024) ‘The Gut Microbiota and Diabetes: Research, Translation, and Clinical Applications—2023 Diabetes, Diabetes Care, and Diabetologia Expert Forum’, Diabetes Care, 47, pp. 1491–1508. Available at: https://doi.org/10.2337/dci24-0052.

Göldi, Andreas et al. (2024) ‘Noninvasive Disease Assessment in Eosinophilic Esophagitis With Fractionated Exhaled Nitric Oxide, Blood, and Fecal Biomarkers’, Journal of Clinical Gastroenterology [Preprint]. Available at: https://doi.org/10.1097/MCG.0000000000002068.

Kaymak, Tanay and Niess, Jan Hendrik (2024) ‘Three-Dimensional Cell Culture Models to Investigate the Epithelial Barrier in Eosinophilic Esophagitis’, Journal of Visualized Experiments, 2024. Available at: https://doi.org/10.3791/66503.

Woelfel, Simon et al. (2024) ‘XBB.1.5-Adapted COVID-19 mRNA Vaccines but Not Infections With Previous Omicron Variants Boost Neutralisation Against the SARS-CoV-2 JN.1 Variant in Patients With Inflammatory Bowel Disease’, Alimentary Pharmacology and Therapeutics [Preprint]. Available at: https://doi.org/10.1111/apt.18349.

Miyamoto K et al. (2023) ‘The gut microbiota-induced kynurenic acid recruits GPR35-positive macrophages to promote experimental encephalitis’, Cell Reports, 42(8), p. 113005. Available at: https://doi.org/10.1016/j.celrep.2023.113005.

Kaymak, Tanay et al. (2023) ‘IL-20 subfamily cytokines impair the oesophageal epithelial barrier by diminishing filaggrin in eosinophilic oesophagitis’, Gut, 72(5), pp. 821–833. Available at: https://doi.org/10.1136/gutjnl-2022-327166.

Rohm, Theresa V. et al. (2022) ‘Targeting colonic macrophages improves glycemic control in high-fat diet-induced obesity’, Communications Biology, 5(1). Available at: https://doi.org/10.1038/s42003-022-03305-z.

Jordi, Sebastian Bruno Ulrich et al. (2022) ‘The personality traits activity, self-reproach, and negative affect jointly predict clinical recurrence, depressive symptoms, and low quality of life in inflammatory bowel disease patients’, Journal of Gastroenterology, 57(11), pp. 848–866. Available at: https://doi.org/10.1007/s00535-022-01902-7.

Casadó-Llombart S et al. (2022) ‘Experimental and genetic evidence for the impact of CD5 and CD6 expression and variation in inflammatory bowel disease’, Frontiers in Immunology, 13, p. 966184. Available at: https://doi.org/10.3389/fimmu.2022.966184.

Kaymak T, Hruz P and Niess JH (2022) ‘Immune system and microbiome in the esophagus: implications for understanding inflammatory diseases’, FEBS Journal, 289(16), pp. 4758–4772. Available at: https://doi.org/10.1111/febs.16103.

Müller A et al. (2022) ‘[The IBD-Control questionnaire: German translation and validation of the standardized questionnaire for Patient Reported Outcome Measurement in inflammatory bowel disease].’, Zeitschrift fur Gastroenterologie, 60(6), pp. 911–926. Available at: https://doi.org/10.1055/a-1482-8642.

Jordi, Sebastian Bruno Ulrich et al. (2022) ‘Depressive Symptoms Predict Clinical Recurrence of Inflammatory Bowel Disease’, Inflammatory Bowel Diseases, 28(4), pp. 560–571. Available at: https://doi.org/10.1093/ibd/izab136.

Melhem, Hassan et al. (2022) ‘Epithelial GPR35 protects from Citrobacter rodentium infection by preserving goblet cells and mucosal barrier integrity’, Mucosal Immunology, 15(3), pp. 443–458. Available at: https://doi.org/10.1038/s41385-022-00494-y.

Walldorf J et al. (2022) ‘The Selective 5-HT1A Agonist SR57746A Protects Intestinal Epithelial Cells and Enteric Glia Cells and Promotes Mucosal Recovery in Experimental Colitis’, Inflammatory Bowel Diseases, 28(3), pp. 423–433. Available at: https://doi.org/10.1093/ibd/izab191.

Lett, Martin J et al. (2022) ‘Stimulatory MAIT cell antigens reach the circulation and are efficiently metabolised and presented by human liver cells’, Gut, 71, pp. 2526–2538. Available at: https://doi.org/10.1136/gutjnl-2021-324478.

Serra, Eva Gonçalves et al. (2022) ‘Author Correction: Somatic mosaicism and common genetic variation contribute to the risk of very-early-onset inflammatory bowel disease (Nature Communications, (2020), 11, 1, (995), 10.1038/s41467-019-14275-y)’, Nature Communications, 13. Available at: https://doi.org/10.1038/s41467-022-31010-2.

Ledergerber M. et al. (2021) ‘Abdominal pain in patients with inflammatory bowel disease: association with single-nucleotide polymorphisms prevalent in irritable bowel syndrome and clinical management’, BMC Gastroenterology, 21(1). Available at: https://doi.org/10.1186/s12876-021-01622-x.

Melhem H, Regan-Komito D and Niess JH (2021) ‘Mucins dynamics in physiological and pathological conditions’, International Journal of Molecular Sciences, 22(24). Available at: https://doi.org/10.3390/ijms222413642.

Kaya B, Melhem H and Niess JH (2021) ‘GPR35 in Intestinal Diseases: From Risk Gene to Function’, Frontiers in Immunology, 12, p. 717392. Available at: https://doi.org/10.3389/fimmu.2021.717392.

Sutter M, Hruz P and Niess JH (2021) ‘High Serum Creatine Kinase Levels in Infliximab and Vedolizumab-Treated Inflammatory Bowel Disease Patients’, Inflammatory Intestinal Diseases, 6(3), pp. 165–174. Available at: https://doi.org/10.1159/000518264.

Jordi S.B.U. et al. (2021) ‘Type D personality is associated with depressive symptoms and clinical activity in inflammatory bowel disease’, Alimentary Pharmacology and Therapeutics, 54(1), pp. 53–67. Available at: https://doi.org/10.1111/apt.16365.

Rohm TV et al. (2021) ‘Obesity in Humans Is Characterized by Gut Inflammation as Shown by Pro-Inflammatory Intestinal Macrophage Accumulation’, Frontiers in Immunology, 12, p. 668654. Available at: https://doi.org/10.3389/fimmu.2021.668654.

Herrema H and Niess JH (2020) ‘Intestinal microbial metabolites in human metabolism and type 2 diabetes’, Diabetologia, 63(12), pp. 2533–2547. Available at: https://doi.org/10.1007/s00125-020-05268-4.

Serra E.G. et al. (2020) ‘Somatic mosaicism and common genetic variation contribute to the risk of very-early-onset inflammatory bowel disease’, Nature Communications, 11(1). Available at: https://doi.org/10.1038/s41467-019-14275-y.

Kaya B et al. (2020) ‘Lysophosphatidic Acid-Mediated GPR35 Signaling in CX3CR1+ Macrophages Regulates Intestinal Homeostasis’, Cell Reports, 32(5), p. 107979. Available at: https://doi.org/10.1016/j.celrep.2020.107979.

Rybinski F et al. (2020) ‘Amoebic Liver Abscess in Crohn Disease Treated with Ustekinumab’, 26(7). Available at: https://doi.org/10.1093/ibd/izaa101.

Schneider T et al. (2020) ‘The copper/zinc ratio correlates with markers of disease activity in patients with inflammatory bowel disease’, Crohn’s and Colitis 360, 2(1), p. otaa001. Available at: https://doi.org/10.1093/crocol/otaa001.

Melhem H et al. (2019) ‘Metabolite-sensing G protein-coupled receptors connect the diet-microbiota-metabolites axis to inflammatory bowel disease’, Cells, 8(5). Available at: https://doi.org/10.3390/cells8050450.

Niess JH and Francés R (2019) ‘Editorial: The IL-20 cytokines and related family members in immunity and diseases’, 10(AUG). Available at: https://doi.org/10.3389/fimmu.2019.01976.

Niess JH, Kaymak T and Hruz P (2019) ‘[The Role of the Exposome in the Emergence of Chronic Inflammatory Bowel Diseases].’, Therapeutische Umschau. Revue therapeutique, 75(5), pp. 261–270. Available at: https://doi.org/10.1024/0040-5930/a000998.

Pillai, Nadia et al. (2019) ‘Evaluating the cost-effectiveness of early compared to late or no biologic treatment to manage Crohn’s disease using real world data’, Journal of Crohn’s & colitis, 14(4), pp. 490–500. Available at: https://doi.org/10.1093/ecco-jcc/jjz169.

Radulovic K et al. (2019) ‘NLRP6 deficiency in CD4 T cells decreases T cell survival associated with increased cell death’, Journal of Immunology, 203(2), pp. 544–556. Available at: https://doi.org/10.4049/jimmunol.1800938.

Yilmaz, Bahtiyar et al. (2019) ‘Publisher Correction: Microbial network disturbances in relapsing refractory Crohn’s disease (Nature Medicine, (2019), 25, 2, (323-336), 10.1038/s41591-018-0308-z)’, Nature Medicine, 25(4), p. 701. Available at: https://doi.org/10.1038/s41591-019-0411-9.

Caviezel D et al. (2018) ‘High Prevalence of Vitamin D Deficiency among Patients with Inflammatory Bowel Disease.’, Inflammatory intestinal diseases. 28.06.2018, 2(4), pp. 200–210. Available at: https://doi.org/10.1159/000489010.

Raduolovic K et al. (2018) ‘Injections of Lipopolysaccharide into Mice to Mimic Entrance of Microbial-derived Products After Intestinal Barrier Breach.’, (135). Available at: https://doi.org/10.3791/57610.

Kaymak T et al. (2018) ‘Low Discontinuation Rate of Infliximab Treatment in Steroid-Dependent/Refractory Crohn’s Disease Patients.’, Inflammatory intestinal diseases. 21.02.2018, 2(3), pp. 171–179. Available at: https://doi.org/10.1159/000486676.

Niess JH, Hruz P and Kaymak T (2018) ‘The Interleukin-20 Cytokines in Intestinal Diseases.’, Frontiers in immunology, 9, p. 1373. Available at: https://doi.org/10.3389/fimmu.2018.01373.

Piñero P et al. (2017) ‘IL26 modulates cytokine response and anti-TNF consumption in Crohn’s disease patients with bacterial DNA.’, Journal of molecular medicine (Berlin, Germany). 06.09.2017, 95(11), pp. 1227–1236. Available at: https://doi.org/10.1007/s00109-017-1585-6.

Steinert A et al. (2017) ‘The Stimulation of Macrophages with TLR Ligands Supports Increased IL-19 Expression in Inflammatory Bowel Disease Patients and in Colitis Models.’, Journal of immunology (Baltimore, Md. : 1950). 01.09.2017, 199(7), pp. 2570–2584. Available at: https://doi.org/10.4049/jimmunol.1700350.

Pittet, Valerie et al. (2017) ‘Patient self-reported concerns in inflammatory bowel diseases: A genderspecific subjective quality-of-life indicator’, PLoS ONE, 12(2). Available at: https://doi.org/10.1371/journal.pone.0171864.

Dawson, H. et al. (2016) ‘Macroscopy predicts tumor progression in gastric cancer: A retrospective patho-historical analysis based on Napoleon Bonaparte’s autopsy report’, Digestive and Liver Disease, 48(11), pp. 1378–1385. Available at: https://doi.org/10.1016/j.dld.2016.07.013.

Heimgartner, B. et al. (2016) ‘Successful Treatment of Small Intestinal Bleeding in a Crohn’s Patient with Noncirrhotic Portal Hypertension by Transjugular Portosystemic Shunt Placement and Infliximab Treatment’, Case Reports in Gastroenterology, 10(3), pp. 589–595. Available at: https://doi.org/10.1159/000450541.

Li, Dalin et al. (2016) ‘A Pleiotropic Missense Variant in SLC39A8 Is Associated With Crohn’s Disease and Human Gut Microbiome Composition’, Gastroenterology, 151(4), pp. 724–732. Available at: https://doi.org/10.1053/j.gastro.2016.06.051.

Rossini, Valerio et al. (2016) ‘Development of an Antigen-driven Colitis Model to Study Presentation of Antigens by Antigen Presenting Cells to T Cells’, Journal of Visualized Experiments, (115), p. e54421. Available at: https://doi.org/10.3791/54421.

Steinert, Anna, Radulovic, Katarina and Niess, Jan (2016) ‘Gastro-intestinal tract: The leading role of mucosal immunity’, Swiss Medical Weekly, 146, p. w14293. Available at: https://doi.org/10.4414/smw.2016.14293.

Radulovic, K. and Niess, J. H. (2015) ‘CD69 Is the Crucial Regulator of Intestinal Inflammation: A New Target Molecule for IBD Treatment?’, Journal of Immunology Research, 2015, p. 497056. Available at: https://doi.org/10.1155/2015/497056.

Rossini V et al. (2014) ‘CX3CR1⁺ cells facilitate the activation of CD4 T cells in the colonic lamina propria during antigen-driven colitis.’, Mucosal immunology. 16.10.2013, 7(3), pp. 533–48. Available at: https://doi.org/10.1038/mi.2013.70.

Niess, Jan Hendrik and Danese, Silvio (2014) ‘Anti-TNF and skin inflammation in IBD: a new paradox in gastroenterology?’, Gut, 63(4), pp. 533–5. Available at: https://doi.org/10.1136/gutjnl-2013-304683.

Schulz, O. et al. (2014) ‘Hypertrophy of infected Peyer’s patches arises from global, interferon-receptor, and CD69-independent shutdown of lymphocyte egress’, Mucosal Immunology, 7(4), pp. 892–904. Available at: https://doi.org/10.1038/mi.2013.105.

Posovszky C et al. (2013) ‘Age-of-onset-dependent influence of NOD2 gene variants on disease behaviour and treatment in Crohn’s disease.’, BMC gastroenterology. 02.05.2013, 13, p. 77. Available at: https://doi.org/10.1186/1471-230x-13-77.

Manta C et al. (2013) ‘CX(3)CR1(+) macrophages support IL-22 production by innate lymphoid cells during infection with Citrobacter rodentium.’, Mucosal immunology. 01.08.2012, 6(1), pp. 177–88. Available at: https://doi.org/10.1038/mi.2012.61.

Neu C et al. (2013) ‘CD14-dependent monocyte isolation enhances phagocytosis of listeria monocytogenes by proinflammatory, GM-CSF-derived macrophages.’, PloS one. 11.06.2013, 8(6), p. e66898. Available at: https://doi.org/10.1371/journal.pone.0066898.

Radulovic K et al. (2013) ‘The early activation marker CD69 regulates the expression of chemokines and CD4 T cell accumulation in intestine.’, PloS one. 12.06.2013, 8(6), p. e65413. Available at: https://doi.org/10.1371/journal.pone.0065413.

Fatima, Sabiha et al. (2003) ‘CD26-/DPP IV-Positive Lymphocytes in Murine Acute Experimental Colitis’, J Investig Allergol Clin Immunol., pp. 345–350. Available at: https://doi.org/10.1007/0-306-47920-6_41.